KEGG   NETWORK: N01062
Entry
N01062                      Network                                
Name
Mutation-activated MET to RAS-ERK signaling pathway
Definition
MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK
  Expanded
4233v4 -> 2885 -> (6654,6655) -> (3265,3845,4893) -> (369,673,5894) -> (5604,5605) -> (5594,5595)
Class
nt06266 Non-small cell lung cancer
nt06210 ERK signaling (cancer)
Type
Variant
Pathway
hsa05223  Non-small cell lung cancer
Disease
H00014  Non-small cell lung cancer
Gene
4233  MET; MET proto-oncogene, receptor tyrosine kinase
2885  GRB2; growth factor receptor bound protein 2
6654  SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1
6655  SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2
3265  HRAS; HRas proto-oncogene, GTPase
3845  KRAS; KRAS proto-oncogene, GTPase
4893  NRAS; NRAS proto-oncogene, GTPase
369  ARAF; A-Raf proto-oncogene, serine/threonine kinase
673  BRAF; B-Raf proto-oncogene, serine/threonine kinase
5894  RAF1; Raf-1 proto-oncogene, serine/threonine kinase
5604  MAP2K1; mitogen-activated protein kinase kinase 1
5605  MAP2K2; mitogen-activated protein kinase kinase 2
5594  MAPK1; mitogen-activated protein kinase 1
5595  MAPK3; mitogen-activated protein kinase 3
Variant
4233v4 (MET*)  MET exon 14 skipping
Reference
PMID:28443282
  Authors
Sundar R, Chenard-Poirier M, Collins DC, Yap TA
  Title
Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer.
  Journal
Front Med (Lausanne) 4:39 (2017)
DOI:10.3389/fmed.2017.00039
Reference
PMID:25971938
  Authors
Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, Akimov M, Bufill JA, Lee C, Jentz D, Hoover R, Ou SH, Salgia R, Brennan T, Chalmers ZR, Jaeger S, Huang A, Elvin JA, Erlich R, Fichtenholtz A, Gowen KA, Greenbowe J, Johnson A, Khaira D, McMahon C, Sanford EM, Roels S, White J, Greshock J, Schlegel R, Lipson D, Yelensky R, Morosini D, Ross JS, Collisson E, Peters M, Stephens PJ, Miller VA
  Title
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
  Journal
Cancer Discov 5:850-9 (2015)
DOI:10.1158/2159-8290.CD-15-0285
Reference
PMID:28502721
  Authors
Lee GD, Lee SE, Oh DY, Yu DB, Jeong HM, Kim J, Hong S, Jung HS, Oh E, Song JY, Lee MS, Kim M, Jung K, Kim J, Shin YK, Choi YL, Kim HR
  Title
MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values.
  Journal
J Thorac Oncol 12:1233-1246 (2017)
DOI:10.1016/j.jtho.2017.04.031
Reference
PMID:27794501
  Authors
Drilon A, Cappuzzo F, Ou SI, Camidge DR
  Title
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
  Journal
J Thorac Oncol 12:15-26 (2017)
DOI:10.1016/j.jtho.2016.10.014
Reference
PMID:22128289
  Authors
Organ SL, Tsao MS
  Title
An overview of the c-MET signaling pathway.
  Journal
Ther Adv Med Oncol 3:S7-S19 (2011)
DOI:10.1177/1758834011422556
LinkDB

DBGET integrated database retrieval system